Landmark Bio
A Project Manager at Landmark Bio manages complex projects, develops tools, and supports cross-functional teams in the cell and gene therapy field.
Landmark Bio is a cell and gene therapy manufacturing company that develops innovative technologies, products, and services to bridge the gap from bench to patient. They provide end-to-end support—process development, scale-up and GMP manufacturing, analytical testing, and regulatory-ready workflows—to translate research into clinical‑grade therapies. Focused on enabling academic groups and biotech partners, Landmark Bio offers scalable, compliant solutions and partnership models to accelerate commercialization and bring therapies to patients.
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
Jan 6, 2026
Artis expands its territory with acquisition of Landmark Bio for cell and gene manufacturing
Apr 2, 2025
Artis BioSolutions Emerges from Stealth, Acquires Landmark Bio
Apr 3, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Landmark Bio.
Landmark Bio didn’t post a salary, so this is our estimate from similar listings.
New genetic medicine CDMO acquires Landmark Bio
Apr 2, 2025
Sr. Director Marketing
Genetix Biotherapeutics
Senior Account Director, Cell & Gene Therapy
Catalent
Senior Director, Product Quality Engineering
Bristol Myers Squibb
Cell and Gene Therapy (CGT) Quality Program Owner m/f/d
JobAps
Manufacturing Sciences and Technology (MSAT) Process Engineer
Orca Bio
Director, Cell & Gene Therapy Research Technology (Boston)
Vertex